Abbreviations: BA = bone age; BMI = body mass index; BU = busulfan; CA = chronological age; DEXA = dual-energy X-ray absorptiometry assessment; GHD = growth hormone deficiency; HSCT = hematopoietic stem cell transplantation; SDS = standard deviation score.
Hematopoietic stem cell transplantation (HSCT) has become an important therapeutic modality for leukemia. However, this treatment has significant adverse effects on the endocrine system, including bone health. 1 The amount of bone gained during puberty is the main contributor to peak bone mass, which is a major determinant of osteoporosis and fracture risk in the elderly. 2 Patients who do not reach the optimal bone mineral density (BMD) during childhood, particularly during adolescence, might be more likely to suffer from osteoporotic fractures later in life. 3 International Society for Clinical Densitometry Pediatric Official Positions recommends a bone densitometric assessment in diseases secondary to cancer or therapies with adverse effects on bone health. 4 However, limited data about assessment of osteoporosis in adolescents with leukemia after HSCT are available. In this study, we aim to investigate the reduced bone mass and endocrinopathy/treatment factors associated with low BMD in adolescents 414 years with hematologic malignancy after HSCT using a Korean BMD reference. 5, 6 This is a cross-sectional study. The medical records of each patient were reviewed retrospectively. Between September 2009 and September 2014, 170 children and adolescents with leukemia after receiving HSCT at the Catholic BMT Center at Seoul St Mary's Hospital had dual-energy X-ray absorptiometry assessment (DEXA). Among them, six participants who had DEXA checked within 6 months of HSCT, 82 children o 14 years and 21 patients having nonmalignant disease were excluded. Ultimately, our study population included 61 adolescents (males = 33, females = 28); (Table 1) .
All anthropometry data including height and weight were calculated to a Z-score based on the Korean reference data. 7 Bone age (BA) was determined using the Greulich and Pyle method. 8 BMDs of lumbar spine (LS) and femoral neck (FN) were measured serially by Lunar Prodigy Advance DXA bone densitometry (Lunar Corporation, General Electric, Madison, WI, USA) with pediatric software (ver. enCore 2005 9.15.010, GE Lunar Corporation). BMDs of LS and FN of patients were calculated to a Z-score based on the Korean reference data. 5 The LS and FN BMD Z-score was adjusted for body size including height and weight using predicted BMD Z-scores. 6 In this article, subjects were defined as low BMD when adjusting LS BMD standard deviation score (SDS) for current body size was o − 2.0. Acute GvHD was graded according to the previously established criteria. 9 Acute GvHD outcomes included acute GvHD grade II-IV. Chronic GvHD was classified as clinically limited or extensive according to the Revised Seattle Classification. 10 Patients with increased thyroid-stimulating hormone and reduced free thyroxine (fT 4 ) after HSCT were diagnosed as having hypothyroidism. Subjects with a height below the third percentile for age and sex and absent or low level of growth hormone (GH, o10 ng/mL) in response to two provocative tests were diagnosed as growth hormone deficiency (GHD). Adolescents who showed incomplete pubertal development and increased folliclestimulating hormone concentration (420 IU/L) after HSCT were diagnosed as having hypogonadism.
The CA and BA of subjects (n = 61) at DEXA were 16.6 ± 1.3 and 15.6 ± 2.0 years. The CA of subjects at HSCT was 12.4 ± 3.8 years, and the interval between HSCT and DEXA was 4.2 ± 3.7 years. The patients (lymphoid leukemia = 28 and myeloid leukemia = 33) underwent TBI-based (n = 31) and busulfan (BU)-based (n = 30) preparative regimens for HSCT. The SDS of weight, height and BMI of subjects at DEXA were − 1.5 ± 2.5, − 1.3 ± 1.8 and − 0.75 ± 1.8, respectively. The subjects having GvHD (acute GvHD = 35 and chronic GvHD = 33) were treated with steroids (n = 35) or cyclosporine (n = 48) over a period of 6 months. Subjects after HSCT showed adverse effects on the endocrine system including hypothyroidism (n = 11), GHD (n = 14) and hypogonadism (n = 35); (Table 1) .
Before adjusting LS BMD SDS for current body size, 35 patients (57.4%) of LS BMD SDS were o − 2.0. In these 35 patients, BA (14.9 ± 2.2 vs 16.6 ± 1.2, P o 0.001), weight-SDS (−2.4 ± 2.5 vs − 0.2 ± 1.9, P o 0.000), height-SDS (−1.9 ± 1.8 vs − 0.4 ± 1.5, P o0.000) and BMI-SDS (−1.3 ± 1.8 vs 0.1 ± 1.5, P o 0.002) were lower than those of the subjects with over − 2.0 of LS BMD SDS. In these 35 patients, the incidences of hypogonadism (25 (71.4%) vs 10 (38.5%), Po 0.018) and GHD (14 (40.0%) vs 0 (0%), P o 0.000) were higher than those of the subjects with over − 2.0 of LS BMD SDS. Between the two groups, there were no significant differences in sex, CA at DEXA and at HSCT, diagnosis, preparative regimen for HSCT, acute and chronic GvHD, steroid and cyclosporine used for GvHD over 6 months and hypothyroidisms. After adjusting LS BMD SDS for current body size, 23 patients (37.7%) were determined to have low BMD. In low-BMD group, the incidences of chronic GvHD (17 (73.9%) vs 16 (42.1%), P o 0.019) and hypogonadism (18 (78.3%) vs 17 (44.7%), P o0.016) were higher than the subjects with over − 2.0 of LS BMD SDS. There were no significant differences in sex, CA at HSCT and DEXA, BA at DEXA, or SDS of weight, height or BMI, diagnosis, preparative regimen for HSCT, acute GvHD, steroid or cyclosporine treatment for GvHD over 6 months, GHD and hypothyroidism between the two groups ( Table 2 ).
In the univariate logistic regression analysis, steroid used for GvHD over 6 months (OR = 3.2; 95% CI, 1.0-9.7, P o0.046) and hypogonadism (odds ratio (OR) = 4.4; 95% confidence interval (CI), 1.4-14.5, P o 0.013) were associated with low BMD. In a multivariate logistic regression analysis, hypogonadism was associated with low BMD (OR = 3.9; 95% CI, 1.2-13.2, P o 0.026).
Low bone mass might increase the risk of bone fracture, but shorter people had a reduced risk of bone fracture. 11 BMD can be reduced in children with GHD as a consequence of small stature, and care must be taken when comparing BMD in GHD patients with that in control subjects. 12 The Pediatric Position Development Conference recommended that spinal BMD in children with short stature or growth delay be adjusted using the height Z-score. 13 In this report, the LS and FN BMD SDS were adjusted for body size including height and weight using the Korean reference values of predicted Z-score. 6 In comparison before and after adjusting BMD SDS for current body size, LS BMD SDS (−2.3 ± 2.2) and FN BMD SDS (−2.3 ± 1.7) of subjects were increased to − 1.5 ± 1.7 and − 1.4 ± 1.4, respectively, after height adjustment.
The statistical significance of the higher incidence of GHD in the subjects with o − 2.0 of LS BMD SDS (before adjusting for current height) was nullified after adjusting LS BMD SDS for current body size (data not shown). Inspite of this disappearance of statistical significance, there is no doubt that GHD is associated with osteopenia in children after HSCT. 14 In the univariate logistic regression analysis, prolonged steroid treatment for GvHD was a significant risk factor of low BMD after HSCT. Long-term corticosteroid therapy has deleterious effects as a consequence of decreased bone formation and variable effects on bone resorption, and the growing skeleton can be especially susceptible to these effects. 15 In multivariate logistic regression analysis, hypogonadism was a significant risk factor of low BMD after HSCT. Hypogonadism during puberty has been known to lead to insufficient accretion of bone mass, and leads to accelerated loss of bone mass in later life. 12 In conclusion, one-third of adolescents with leukemia treated with HSCT showed low BMD. Bone health is an important endocrine and musculoskeletal issue in childhood cancer survivors. Early recognition and prevention of osteoporosis should be integral components of follow-up for long-term HSCT survivors. New strategies of national health insurance services to cover the medical costs of DEXA in young HSCT survivors might be necessary. Abbreviations: BA = bone age; BU = busulfan; CA = chronological age; DEXA = dual-energy X-ray absorptiometry assessment; FN = femur neck; GHD = growth hormone deficiency; HSCT = hematopoietic stem cell transplantation; Low BMD = when adjusting lumbar spine (LS) bone mineral density (BMD) standard deviation score (SDS) for current body size was o −2.0.
5,6

